Navigation Links
New licensing agreement to maximize AIDS drug development

Longtime collaborators CONRAD and the Biosyn Division of Cellegy Pharmaceuticals, Inc. today announced a non-exclusive licensing agreement to research and develop Biosyn-patented microbicides for the prevention of HIV and other sexually transmitted diseases.

The three microbicides covered under the agreement are in various stages of development and work under different mechanisms of action. They include: Savvy, which is currently in Phase III clinical trials in the U.S. and Africa; UC781 which is in expanded Phase II trials in the U.S and Thailand and Cyanovirin-N which is in preclinical testing. Henry Gabelnick, Ph.D., executive director of CONRAD says, "This agreement is great news for everyone interested in developing an effective microbicide. The more partnerships we have like this one, the better our potential is for getting an effective product ready for distribution."

"I am delighted for our two organizations to enter into this agreement. We have collaborated for many years on all aspects of our microbicide development programs, and we have a deep respect for each other's knowledge and expertise. With CONRAD, we feel we have a capable and experienced partner to work with us toward approval of these critically important products," said Anne-Marie Corner, Senior Vice President of Cellegy Pharmaceuticals.Currently, the highest rates of infection in women are in sub-Saharan Africa and rates are increasing in women in South and Southeast Asia.

CONRAD has been involved in the research of nearly every microbicide currently in clinical trials. They are currently managing a second Phase III trial of a microbicide called Ushercell in Uganda and South Africa, Benin, Burkina Faso and two centers in India. The trials will evaluate Ushercell for the prevention of HIV infection among 2,574 adult women at high risk of acquiring HIV. This study will also assess incidence of genital gonorrhea and chlamydia.

CONRAD is a cooperating agen cy of USAID committed to improving reproductive health by expanding the contraceptive choices of women and men and by helping to prevent the transmission of HIV/AIDS and other sexually transmitted diseases. CONRAD is administered through the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA, with the main office located in Arlington, VA.

Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention; and, gastrointestinal disorders. Biosyn, Inc is a wholly owned subsidiary of Cellegy Pharmaceuticals.

CellegesicTM (nitroglycerin ointment), branded Rectogesic® outside the United States, is approved and is being marketed in the United Kingdom by ProStrakan, for the treatment of pain associated with chronic anal fissures. A similar formulation of Rectogesic is currently being sold in Australia, New Zealand, Singapore and South Korea.

FortigelTM (testosterone gel), branded Tostrex® outside the United States, is marketed in Sweden for the treatment of male hypogonadism also by ProStrakan. Approvals of Rectogesic and Tostrex by the other member states of the European Union are being sought through the Mutual Recognition Procedure.


Source:Rational PR

Related biology news :

1. Genomatix, AAAS ink agreement
2. A much-needed shot in the arm for HIV vaccine development
3. Clam embryo study shows pollutant mixture adversely affects nerve cell development
4. Zebrafish may hold key to understanding human nerve cell development
5. Scientists identify new model Of NK cell development
6. Influenza vaccine uses insect cells to speed development
7. Liposome finding implies electrical effect on cell development
8. Multi-purpose protein regulates new protein synthesis and immune cell development
9. Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development
10. Scientists find microRNAs regulate plant development
11. MicroRNA tweaks protein that controls early heart development
Post Your Comments:

(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: